nach oben

International Journal of Colorectal Disease

Erschienen in:

06.09.2019 | Review

An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease

verfasst von: Mahmoud Ahmed Ebada, Abdelmagid M. Elmatboly, Ahmed Said Ali, Ahmed Mohamed Ibrahim, Notila Fayed, Ahmed Faisal Faisal, Souad Alkanj

Erschienen in: International Journal of Colorectal Disease | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

We aimed to evaluate the efficacy and safety of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease.

Methods

We searched PubMed, Scopus, Ovid, and Web of Science for relevant clinical trials discussing CT-P31 administration for IBD patients either naïve to biological therapy or switched from IFX therapy. Data of the rates of clinical response, clinical remission, and adverse events were extracted and pooled in a random effect model meta-analysis using CMA version 2.

Results

Thirty-two studies with a total of 3464 IBD patients treated with CT-P13 were identified. The pooled rates of clinical response among Crohn’s disease (CD) and ulcerative colitis (UC) at 8–14 weeks were 0.81 (95% CI = 0.72 to 0.87) and 0.68 (95% CI = 0.63 to 0.72), respectively, and at 48–63 weeks were 0.69 (95% CI = 0.48 to 0.85) and 0.54 (95% CI = 0.45 to 0.63) respectively. After switching from IFX to CT-P13, the pooled rates of sustained clinical response among CD and UC at 30–32 weeks were 0.84 (95% CI = 0.57 to 0.96) and 0.96 (95% CI = 0.58 to 0.99), respectively, and at 48–63 weeks were 0.51 (95% CI = 0.22 to 0.79) and 0.83 (95% CI = 0.19 to 0.99) respectively. Moreover, adverse events were reported (CD = 0.10, 95% CI 0.04 to 0.22; UC = 0.18, 95% CI 0.05 to 0.15).

Conclusion

CT-P13 is effective and well tolerated in short and long-term periods. Switching to CT-P13 is recommended for the management of IBD.

Nur mit Berechtigung zugänglich

Keil R, Wasserbauer M, Zádorová Z, Hajer J, Drastich P, Wohl P, Beneš M, Bojková M, Svoboda P, Konečný M, Falt P, Vaňásek T, Pešta M, Pešek F, Bouchner L, Koželuhová J, Novotný A, Bartůsková L, Špičák J (2016) Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis. Scand J Gastroenterol 51:1062–1068. https://doi.org/10.3109/00365521.2016.1149883 CrossRefPubMedPubMedCentral

Rutgeerts P, Assche GVAN, Vermeire S (2006) Review article : infliximab therapy for inflammatory bowel disease – seven years on:451–463. https://doi.org/10.1111/j.1365-2036.2006.02786.x

Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Pérez B, Chaaro D, Benítez Roldán A, Merino V, Ramírez G, Caunedo Álvarez A, Romero Gómez M (2017) Effectiveness and safety of CT-P13 (biosimilar infliximab) in patients with inflammatory bowel disease in real life at 6 months. Dig Dis Sci 62:1305–1312. https://doi.org/10.1007/s10620-017-4511-4 CrossRefPubMedPubMedCentral

Jahnsen J, Detlie TE, Vatn S, Ricanek P (2015) Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol 9:S45–S52. https://doi.org/10.1586/17474124.2015.1091308 CrossRef

Jung YS, Il PD, Kim YH et al (2015) Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol 30:1705–1712. https://doi.org/10.1111/jgh.12997 CrossRefPubMed

Alten R, Batko B, Hala T et al (2019) Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54. RMD Open 5:e000876. https://doi.org/10.1136/rmdopen-2018-000876 CrossRefPubMedPubMedCentral

Cohen S, Pablos JL, Pavelka K et al (2019) An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis, vol 3, pp 1–10

Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, Pablos JL, Rizzo W, Hrycaj P, Zhang N, Shergy W, Kaur P (2017) Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis 76:1679–1687. https://doi.org/10.1136/annrheumdis-2016-210459 CrossRefPubMedPubMedCentral

(2017) Curr Rheumatol 2007. 138160

10.

Popova EV, Boyko AN, Bykova OV, Nankina IG, Batysheva TT (2016) Experience of application of Russian biosimilar of interferon beta-1b for treatment of pediatric multiple sclerosis. Zhurnal Nevrol i Psihiatr Im SS Korsakova 116:73–75. https://doi.org/10.17116/JNEVRO20161166173-75 CrossRef

11.

Komaki Y, Yamada A, Komaki F, Micic D, Ido A, Sakuraba A (2017) Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther 45:1043–1057. https://doi.org/10.1111/apt.13990 CrossRefPubMed

12.

Shamseer L, Moher D, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 350:g7647CrossRefPubMed

13.

Higgins JP, Green S (2008) Cochrane handbook for systematic reviews of interventions: Cochrane book series. Cochrane Handb Syst rev Interv Cochrane B Ser 1–649. https://doi.org/10.1002/9780470712184

14.

Reviews C, Reviews C, Library TC Cochrane handbook for systematic reviews of interventions chapter 1: introduction UNDER CONSTRUCTION - PLEASE DO NOT USE Key points. 1–8

15.

Adequate CD, This C CODING MANUAL FOR CASE-CONTROL STUDIES

16.

Raj R, Mikkonen ED, Siironen J et al (2015) Alcohol and mortality after moderate to severe traumatic brain injury: a meta-analysis of observational studies. 1–9. https://doi.org/10.3171/2015.4.JNS141746 CrossRef

17.

Zhang X (2015) Prognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including, pp 2731–2738

18.

Blair HA, Deeks ED (2016) Infliximab biosimilar (CT-P13; infliximab-dyyb): a review in autoimmune inflammatory diseases. BioDrugs 30:469–480. https://doi.org/10.1007/s40259-016-0193-2 CrossRefPubMed

19.

Pereira TV, Patsopoulos NA, Salanti G, Ioannidis JPA (2010) Critical interpretation of Cochran’s Q test depends on power and prior assumptions about heterogeneity. Res Synth Methods 1:149–161. https://doi.org/10.1002/jrsm.13 CrossRefPubMed

20.

Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, Kim HK, Cheon JH, Im JP, Kim YS, Lee SY, Lee SJ (2015) Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol 9:S35–S44. https://doi.org/10.1586/17474124.2015.1091309 CrossRef

21.

Hruba V, Bortlik M, Lukas Jr. M, et al (2017) Infliximab biosimilar (Remsima™) in therapy of inflammatory bowel diseases patients: experience from one tertiary inflammatory bowel diseases centre. Dig Dis 35:91–100. https://doi.org/10.1159/000453343

22.

Smits LJT, Derikx LAAP, de Jong DJ, Boshuizen RS, van Esch AAJ, Drenth JPH, Hoentjen F (2016) Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohn's Colitis 10:1287–1293. https://doi.org/10.1093/ecco-jcc/jjw087 CrossRef

23.

Veloz MFG, Morón JMV, Jiménez MB et al (2018) Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months. Rev Esp Enfermedades Dig 110:564–570. https://doi.org/10.17235/REED.2018.5368/2017 CrossRef

24.

Ratnakumaran R, To N, Gracie DJ et al (2018) Efficacy and tolerability of initiating , or switching to , infliximab biosimilar CT-P13 in inflammatory bowel disease ( IBD ): a large single-Centre experience. Scand J Gastroenterol 0:1–8. https://doi.org/10.1080/00365521.2018.1464203 CrossRef

25.

Komaki Y, Yamada A, Komaki F, et al (2017) Alimentary pharmacology and therapeutics systematic review with meta-analysis : the efficacy and safety of CT-P13 , a biosimilar of anti-tumour necrosis factor- a agent (infliximab), in in flammatory bowel diseases. 1–15. https://doi.org/10.1111/apt.13990

26.

Midtgard IP, Lundin KEA, Dvergsnes K et al (2017) Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 389:2304–2316. https://doi.org/10.1016/s0140-6736(17)30068-5 CrossRef

27.

Pesegova M, Ye BD, Lee SJ, et al (2018) 814 - Phase Iii randomized controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: 1-year maintenance and switching results. Gastroenterology 154:S-167-S-168. https://doi.org/10.1016/s0016-5085(18)30972-7

28.

Ratnakumaran R, To N, Gracie DJ et al (2018) Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. Scand J Gastroenterol 53:700–707. https://doi.org/10.1080/00365521.2018.1464203 CrossRefPubMed

29.

Noble CL, Watson EF, Merchant LM et al (2018) Implementation of CT-P13 via a managed switch programme in Crohn’s disease: 12-month real-world outcomes. Dig Dis Sci 64:1660–1667. https://doi.org/10.1007/s10620-018-5406-8 CrossRefPubMed

30.

Beloso C, Souto J, Fábregat M, Romanelli G, Javiel G MA (2018) World journal of. World J Diabetes 9:157–164. https://doi.org/10.5321/wjs.v2.i3.40

31.

Arguëlles-Arias F, Guerra Veloz MF, Perea Amarillo R et al (2017) Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results. Eur J Gastroenterol Hepatol 29:1290–1295. https://doi.org/10.1097/MEG.0000000000000953 CrossRefPubMedPubMedCentral

32.

Lim YJ, Kang HW, Lee SE et al (2014) Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci 60:951–956. https://doi.org/10.1007/s10620-014-3392-z CrossRefPubMed

33.

Sieczkowska-Golub J, Meglicka M, Plocek A, Banaszkiewicz A, Jarzębicka D, Toporowska-Kowalska E, Gawronska A, Oracz G, Kierkus J (2017) Induction therapy with biosimilar infliximab in children with Crohn disease. J Pediatr Gastroenterol Nutr 65:285–288. https://doi.org/10.1097/MPG.0000000000001643 CrossRefPubMed

34.

Sieczkowska J, Banaszkiewicz A, Plocek A, Jarzebicka D P430 Assessment of safety and efficacy of biosimilar infliximab in children with Crohn disease : a preliminary report . P429 Influence of Disease Course on Therapeutic Effect of IFX in Crohn ’ s disease P431 Serology panel for prediction relapse after dis. 431

35.

Gecse KB, Lovász BD, Farkas K et al (2016) Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort. J Crohns Colitis 10:133–140. https://doi.org/10.1093/ecco-jcc/jjv220 CrossRefPubMed

36.

Hlavaty T, Krajcovicova A, Sturdik I et al (2016) Biosimilar infl iximab CT-Pwy treatment in patients with infl am matory bowel diseases - a one-year, single-centre retrospective study. Gastroenterol a Hepatol 70:27–36. https://doi.org/10.14735/amgh201627 CrossRef

37.

Nagy F, Farkas K, Rutka M, Ba A (2015) Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn ’ s disease and ulcerative colitis - experiences from a single center. 1–6. https://doi.org/10.1517/14712598.2015.1064893

38.

No Title. https://doi.org/10.1097/MPG.0000000000001643

39.

Hyoung YK, Moon H (2015) Clinical experience of the use of CT-P13 , a biosimilar to infliximab in patients with inflammatory bowel disease : a case series. Dig Dis Sci 951–956. https://doi.org/10.1007/s10620-014-3392-z

40.

Gonczi L, Gecse KB, Vegh Z, et al (2017) Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective Nationwide Cohort. 0:1–8. https://doi.org/10.1097/MIB.0000000000001237

41.

(2015) P329 Infliximab biosimilar in the treatment of inflammatory bowel disease : a Japanese single- cohort observational study P331 Allopurinol and azathioprine co-therapy or thioguanine dose splitting : shifting the shunters in the mercaptopurine pathway in a. 330

42.

Sanchez SDS, Wan H, Streck P, et al Pooled safety analysis of long-term , once-daily multimatrix mesalazine use P540 Efficacy and safety of infliximab ’ s biosimilar ( REMSIMA ) for IBD P539 Outcome of acute severe ulcerative colitis in patients previously exposed to immunosoppressive thera. 349–350

43.

Ostrava H, Republic C, Colentina CH (2017) P420 Effectiveness and safety of biosimilar infliximab ( remsima ) in a real-life setting in 84 patients with Crohn ’ s disease and ulcerative colitis P419 Frequency of inadequate response to anti- tumour necrosis factor therapy in patients with ulcerativ. 51:70–71

44.

Danese S, Neurath M, Kopon A, et al AGA Abstracts AGA Abstracts AGA Abstracts S-168. Gastroenterology 154:S-167–S-168. https://doi.org/10.1016/S0016-5085(18)30972-7

45.

Farkas K, Rutka M, Bálint A et al (2015) Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single center. Expert Opin Biol Ther 15:1257–1262. https://doi.org/10.1517/14712598.2015.1064893 CrossRefPubMed

46.

Bálint A, Rutka M, Kolar M et al (2018) Expert Opinion on Biological Therapy Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis – results from multicenter observational cohort remission in ulcerative colitis – results from multicenter obs. Expert Opin Biol Ther 18:1181–1187. https://doi.org/10.1080/14712598.2018.1530758 CrossRefPubMed

47.

Argüelles-arias F, Fernanda M, Veloz G, et al (2017) Switching from reference in fliximab to CT-P13 in patients with in flammatory bowel disease : 12 months results. 1–6. https://doi.org/10.1097/MEG.0000000000000953

48.

Bergqvist V, Kadivar M, Molin D, et al (2018) Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease. 1–13. https://doi.org/10.1177/1756284818801244

49.

(2016) P337 Switching from originator infliximab to CT-P13 : single-centre experience from the UK P339 Application of Bayesian modelling with infliximab to determine optimal patient-specific regimens P338 Long-term complications in patients with fistulising Croh. 13–14

50.

Plevris N, Jones GR, Jenkinson PW et al (2018) Implementation of CT - P13 via a Managed Switch Programme in Crohn ’ s Disease : 12 - Month Real - World Outcomes. Dig Dis Sci. https://doi.org/10.1007/s10620-018-5406-8

51.

Gastroenterol WJ (2018) World Journal of. 9327

52.

Sieczkowska J, Jarzębicka D, Banaszkiewicz A et al (2016) Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations. J Crohns Colitis 10:127–132. https://doi.org/10.1093/ecco-jcc/jjv233 CrossRefPubMed

53.

Buer LCT, Moum BA, Cvancarova M et al (2017) Switching from Remicade® to Remsima® is well tolerated and feasible: a prospective, open-label study. J Crohns Colitis 11:297–304. https://doi.org/10.1093/ecco-jcc/jjw166 CrossRefPubMed

54.

Olsen IC, Goll GL, Lorentzen M, et al (2017) Articles Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week , randomised ,. 6736:. https://doi.org/10.1016/S0140-6736(17)30068-5

55.

(2018) Efficacy , safety and economic impact of the switch to biosimilar of infliximab in inflammatory bowel disease patients in clinical practice : results of one The long-term efficacy of adalimumab on Crohn ’ s disease comorbid with perianal lesions and poor. 2961572

56.

Nasuno M, Tanaka H, Miyakawa M, et al (2018) Short-term outcomes of adalimumab for patients with Crohn ’ s disease and associated prognostic factors : a multicentre retrospective cohort study Unchanged infliximab serum concentrations after switching from the reference infliximab to the biosimilar CT. 2961608

Titel: An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease
verfasst von: Mahmoud Ahmed Ebada
Abdelmagid M. Elmatboly
Ahmed Said Ali
Ahmed Mohamed Ibrahim
Notila Fayed
Ahmed Faisal Faisal
Souad Alkanj
Publikationsdatum: 06.09.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: International Journal of Colorectal Disease / Ausgabe 10/2019
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-019-03354-7

Neu im Fachgebiet Chirurgie

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Recycling im OP – möglich, aber teuer

05.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO₂-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Im OP der Zukunft läuft nichts mehr ohne Kollege Roboter

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Nur selten Nachblutungen nach Abszesstonsillektomie

03.05.2024 Tonsillektomie Nachrichten

In einer Metaanalyse von 18 Studien war die Rate von Nachblutungen nach einer Abszesstonsillektomie mit weniger als 7% recht niedrig. Nur rund 2% der Behandelten mussten nachoperiert werden. Die Therapie scheint damit recht sicher zu sein.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease